Information  X 
Enter a valid email address

Worldwide Healthcare (WWH)

  Print      Mail a friend

Thursday 30 July, 2020

Worldwide Healthcare

Edison issues review on Worldwide Healthcare Trust

RNS Number : 6472U
Worldwide Healthcare Trust PLC
30 July 2020
 

 

London, UK, 30 July 2020

Edison issues review on Worldwide Healthcare Trust (WWH)

Worldwide Healthcare Trust (WWH) is celebrating its 25th anniversary. Managed by Sven Borho and Trevor Polischuk at OrbiMed, the trust has an enviable absolute and relative performance track record. The managers remain very constructive on the prospects for the global healthcare sector, suggesting that while President Trump has once again focused on the issue of US drug pricing, his 'bark is worse than his bite', and his efforts are a negotiating ploy to get the healthcare industry to the table to discuss reforms. They highlight minimal disruptions at the US Food and Drug Administration (FDA) as a result of the coronavirus and expect an uptick in industry mergers and acquisitions (M&A) in H220 and beyond.

 

WWH's shares regularly trade close to NAV. The current 1.1% premium to cum-income NAV compares to a range of an average 0.3% premium to an average 3.8% discount over the past one, three, five and 10 years. While the trust aims to generate long-term capital growth, it also pays semi-annual dividends. Based on its current share price, WWH offers a 0.7% yield. 


Click here to view the full report.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison:   Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Mel Jenner, +44 (0)20 3077 5720

Sarah Godfrey, +44 (0)20 3681 2519

[email protected]

 

Learn more at   www.edisongroup.com and connect with Edison on: 

LinkedIn  https://www.linkedin.com/company/edison-investment-research  

Twitter   www.twitter.com/Edison_Inv_Res  

YouTube  www.youtube.com/edisonitv  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRARMMTTMTMJBTM

a d v e r t i s e m e n t